Insights
Sensors in Claims: How To Reduce Workplace Injuries
3 MIN READ
We live in world where almost anything can become or have associated with it a sensor that informs a broader system designed to make the world around us more intelligent, convenient, and very often safer. Consider the Fitbit: according to the company, more than 25 million people worldwide actively used their devices in 2017.
Guidewire Connections 2018
Guidewire Connections is the conference for
StateWatch: Bill Review May 2018
2 MIN READ
Keep current with new legislation and its potential effect on your organization. This regulatory update is for informational purposes only, and provides some key highlights on state initiatives that may impact the bill review services Genex provides.
Topical Treatments - Their Impact on Drug Spend and Utilization
1 MIN READ
Topicals place fourth in overall cost among the 10 most expensive drug classes in workers’ comp. These include prescription nonsteroidal anti-inflammatory drugs (NSAIDs) and other formulations, such as creams and patches designed to treat pain.
StateWatch: Bill Review May 2018
2 MIN READ
Keep current with new legislation and its potential effect on your organization. This regulatory update is for informational purposes only, and provides some key highlights on state initiatives that may impact the bill review services Genex provides.
Insurtech: Improving Consumer Experiences and Relationships
Technology is one of the hottest topics in insurance, as Insurtech innovations continue to disrupt the industry. Between improving customer experiences and relationships, helping contain costs and using data to improve decision-making, technology has been and will continue to make significant improvements in Property & Casualty claims handling.
Quarterly Drug Update: Pharmacy Drug Spend
3 MIN READ
CompPharma's 2018 Annual Survey of Prescription Drug Management in Workers' Comp found that, in the past eight years, drug spend has decreased 31.5% among those surveyed in workers’ compensation. Part of this is due to increased focus on dangerous opioid prescribing behaviors and the implementation of state-mandated formularies. Opioid spend has decreased for the same group by around 18.22% in the past year and payers and PBM’s have been able to reduce opioid spend by about one third in the last two years.
Stay Ahead in P&C
Get monthly insights from Enlyte experts to tackle your toughest claims challenges.